Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables (2021 - 2025)

Tg Therapeutics has reported Receivables over the past 5 years, most recently at $305.6 million for Q4 2025.

  • Quarterly results put Receivables at $305.6 million for Q4 2025, up 100.17% from a year ago — trailing twelve months through Dec 2025 was $305.6 million (up 100.17% YoY), and the annual figure for FY2025 was $305.6 million, up 100.17%.
  • Receivables for Q4 2025 was $305.6 million at Tg Therapeutics, up from $265.4 million in the prior quarter.
  • Over the last five years, Receivables for TGTX hit a ceiling of $305.6 million in Q4 2025 and a floor of $88000.0 in Q2 2022.
  • Median Receivables over the past 5 years was $51.6 million (2023), compared with a mean of $86.2 million.
  • Biggest five-year swings in Receivables: crashed 90.55% in 2022 and later soared 19768.18% in 2023.
  • Tg Therapeutics' Receivables stood at $1.4 million in 2021, then tumbled by 93.66% to $88000.0 in 2022, then soared by 64664.77% to $57.0 million in 2023, then surged by 167.9% to $152.7 million in 2024, then soared by 100.17% to $305.6 million in 2025.
  • The last three reported values for Receivables were $305.6 million (Q4 2025), $265.4 million (Q3 2025), and $231.5 million (Q2 2025) per Business Quant data.